Gyre Therapeutics
GYRE
27 hedge funds and large institutions have $2.15M invested in Gyre Therapeutics in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 9 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
0.24% more ownership
Funds ownership: 0% → 0.24% (+0.24%)
7% less funds holding
Funds holding: 29 → 27 (-2)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
56% less capital invested
Capital invested by funds: $4.9M → $2.15M (-$2.75M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$158K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$30.6K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$18.8K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$18K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$16.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$1.05M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$86K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$81.8K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$72K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$30K |
GYRE Hedge Fund Activity: Q4 2016 in Review
27 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q4 2016, worth a combined $2.15M — down 56% from $4.9M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of GYRE and 8 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $158K. The largest seller was BVF Inc, exiting entirely with an estimated $1.05M sold.
- 27 institutional investors held Gyre Therapeutics (GYRE) as of Q4 2016, down from 29 in Q3 2016.
- Funds reported $2.15M of Gyre Therapeutics stock for Q4 2016, down 56% quarter-over-quarter.
- 8 funds opened new Gyre Therapeutics positions in Q4 2016 and 9 closed out, a net change of -1 holder.
- The largest Gyre Therapeutics buyer in Q4 2016 was Renaissance Technologies, an estimated $158K added.
- The largest Gyre Therapeutics seller in Q4 2016 was BVF Inc, an estimated $1.05M sold.
Based on aggregated 13F filings for Q4 2016.